ekb-569 and Adenomatous-Polyposis-Coli

ekb-569 has been researched along with Adenomatous-Polyposis-Coli* in 2 studies

Other Studies

2 other study(ies) available for ekb-569 and Adenomatous-Polyposis-Coli

ArticleYear
Combinations for cancer prevention.
    Nature medicine, 2000, Volume: 6, Issue:9

    Topics: Adenomatous Polyposis Coli; Aminoquinolines; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Mice; Models, Biological; Organic Chemicals; Signal Transduction; Sulindac

2000
Combinatorial chemoprevention of intestinal neoplasia.
    Nature medicine, 2000, Volume: 6, Issue:9

    A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed approximately 20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

    Topics: Adenomatous Polyposis Coli; Aminoquinolines; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Mice; Mice, Mutant Strains; Organic Chemicals; Quinazolines; Sulindac

2000